Results 191 to 200 of about 1,124,835 (219)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin   +11 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

A survey on evolutionary computation for complex continuous optimization

Artificial Intelligence Review, 2021
, Kay Chen Tan, Zhi-Hui Zhan
exaly  

Home - About - Disclaimer - Privacy